Biomarkers for Evaluation of Prostate Cancer Prognosis

  • Esfahani, Maryam (Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) ;
  • Ataei, Negar (Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences) ;
  • Panjehpour, Mojtaba (Department of Clinical Biochemistry & Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences)
  • Published : 2015.04.14


Prostate cancer, with a lifetime prevalence of one in six men, is the second cause of malignancy-related death and the most prevalent cancer in men in many countries. Nowadays, prostate cancer diagnosis is often based on the use of biomarkers, especially prostate-specific antigen (PSA) which can result in enhanced detection at earlier stage and decreasing in the number of metastatic patients. However, because of the low specificity of PSA, unnecessary biopsies and mistaken diagnoses frequently occur. Prostate cancer has various features so prognosis following diagnosis is greatly variable. There is a requirement for new prognostic biomarkers, particularly to differentiate between inactive and aggressive forms of disease, to improve clinical management of prostate cancer. Research continues into finding additional markers that may allow this goal to be attained. We here selected a group of candidate biomarkers including PSA, PSA velocity, percentage free PSA, $TGF{\beta}1$, AMACR, chromogranin A, IL-6, IGFBPs, PSCA, biomarkers related to cell cycle regulation, apoptosis, PTEN, androgen receptor, cellular adhesion and angiogenesis, and also prognostic biomarkers with Genomic tests for discussion. This provides an outline of biomarkers that are presently of prognostic interest in prostate cancer investigation.


Biomarkers;prostate cancer;PSA;prediction of prognosis


  1. Achyut BR, Yang L (2011). Transforming growth factor-${\beta}$ in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology, 141, 1167-78.
  2. Al-Maghrebi M, Kehinde EO, Anim JT, et al (2012). The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer. Intern Urol Nephrol, 44, 1681-9.
  3. Askari F, Parizi MK, Jessri M, et al (2014). Fruit and vegetable intake in relation to prostate cancer in Iranian men: a case-control study. Asian Pac J Cancer Prev, 15, 5223-7.
  4. Bassler TJ Jr, Orozco R, Bassler IC, O'Dowd GJ, Stamey TA (1998). Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology, 52, 1064-9.
  5. Bedolla R, Prihoda TJ, Kreisberg JI, et al (2007). Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res, 13, 3860-7.
  6. Behnsawy HM, Miyake H, Harada K-I, et al (2013). Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Intern, 111, 30-7.
  7. Bensalah K, Lotan Y, Karam JA, et al (2007). New circulating biomarkers for prostate cancer. Prostate Cancer, 11, 112-20.
  8. Berruti A, Dogliotti L, Mosca A, et al (2001). Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol, 12, 153-S7.
  9. Bickers B, Aukim-Hastie C (2009). New molecular biomarkers for the prognosis and management of prostate cancer the post PSA era. Anticancer Res, 29, 3289-98.
  10. Bishoff JT, Freedland SJ, Gerber L, et al (2014). Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol, 192, 409-14.
  11. Bocan EV, Mederle O, Sarb S, et al (2011). Correlation between histopathological form and the degree of neuroendocrine differentiations in prostate cancer. Rom J Morphol Embryol, 52, 1215-8.
  12. Bostwick DG, Burke HB, Djakiew D, et al (2004). Human prostate cancer risk factors. Cancer, 101, 2371-490.
  13. Buhmeida A, Pyrhonen S, Laato M, Collan Y (2006). Prognostic factors in prostate cancer. Diagnostic Pathol, 1, 1-15.
  14. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ (2007). Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology, 70, 685-90.
  15. Cary KC, Cooperberg MR (2013). Biomarkers in prostate cancer surveillance and screening: past, present, and future. Therapeutic Advances Urol, 5, 318-29.
  16. Catalona WJ, Partin AW, Slawin KM, et al (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279, 1542-7.
  17. Chan JM, Stampfer MJ, Ma J, et al (2002). Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Nat Cancer Inst, 94, 1099-106.
  18. Charrier J-P, Tournel C, Michel S, et al (2001). Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis, 22, 1861-6.<1861::AID-ELPS1861>3.0.CO;2-6
  19. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al (2012). Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Modern Pathol, 25, 1543-9.
  20. Chunthapong J, Seftor EA, Khalkhali-Ellis Z, et al (2004). Dual roles of E-cadherin in prostate cancer invasion. J Cellular Biochem, 91, 649-61.
  21. Crawford ED, Scholz MC, Kar AJ, et al (2014). Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin, 30, 1025-31.
  22. Culig Z, Steiner H, Bartsch G, et al (2005). Interleukin-6 regulation of prostate cancer cell growth. J Cellular Biochem, 95, 497-505.
  23. Cuzick J, Berney DM, Fisher G, et al (2012). Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. British J Cancer, 106, 1095-9.
  24. Cuzick J, Swanson GP, Fisher G, et al (2011). Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol, 12, 245-55.
  25. D'Amico AV, Chen M-H, Roehl KA, et al (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New England J Med, 351, 125-35.
  26. Deng Q-W, He B-S, Pan Y-Q, et al (2014). Roles of E-cadherin (CDH1) genetic variations in cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 15, 3705-13.
  27. Di JM, Zhou J, Zhou XL, et al (2009). Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch Med Res, 40, 268-75.
  28. Djavan B, Waldert M, Seitz C, et al (2001). Insulin-like growth factors and prostate cancer. World J Urol, 19, 225-33.
  29. Donovan MJ, Hamann S, Clayton M, et al (2008). Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol, 26, 3923-9.
  30. Doolan G, Benke G, Giles G (2014). An update on occupation and prostate cancer. Asian Pac J Cancer Prev, 15, 501-16.
  31. Eiro N, Bermudez-Fernandez S, Fernandez-Garcia B, et al (2014). Analysis of the expression of interleukins, interferon ${\beta}$, and nuclear factor-${\kappa}B$ in prostate cancer and their relationship with biochemical recurrence. J Immun, 37, 366-73.
  32. Erho N, Crisan A, Vergara IA, et al (2013). Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PloS One, 8, 66855.
  33. Erkal EY, Bora H, Tepeoglu M, et al (2014). Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy. Balkan Med J, 31, 43-9.
  34. Etzioni R, Penson DF, Legler JM, et al (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Nat Cancer Inst, 94, 981-90.
  35. Euling SY, Kimmel CA (2001). Developmental stage sensitivity and mode of action information for androgen agonists and antagonists. Science Total Environ, 274, 103-13.
  36. Fang J, Ding M, Yang L, et al (2007). PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cellular Signal, 19, 2487-97.
  37. Ferdinandusse S, Denis S, Ijlst L, et al (2000). Subcellular localization and physiological role of ${\alpha}$-methylacyl-CoA racemase. J Lipid Res, 41, 1890-6.
  38. Finne P, Auvinen A, Maattanen L, et al (2008). Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <$3.0{\mu}g$ per liter. Eur Urol, 54, 241-482.
  39. Freedland SJ, deGregorio F, Sacoolidge JC, et al (2003). Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol, 169, 1325-30.
  40. Garg M, Dalela D, Goel A, et al (2014). Prevention of prostate cancer with vitamins-current perspectives. Asian Pac J Cancer Prev, 15, 1897-904.
  41. George DJ, Halabi S, Shepard TF, et al (2005). The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res, 11, 1815-20.
  42. Globocan (2012). Prostate cancer: estimated incidence, mortality and prevalence worldwide in 2012 [Online]. Available:
  43. Graefen M, Karakiewicz PI, Cagiannos I, et al (2002). Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol, 167, 1306-9.
  44. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2007). A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res, 13, 7003-11.
  45. Grignon DJ, Caplan R, Sarkar FH, et al (1997). p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst, 89, 158-65.
  46. Halvorsen OJ (2008). Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. APMIS Suppl, 5-62.
  47. Han K-R, Seligson DB, Liu X, et al (2004). Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol, 171, 1117-21.
  48. Hara N, Kasahara T, Kawasaki T, et al (2002). Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood value for the staging of prostate cancer. Clin Cancer Res, 8, 1794-9.
  49. Hicklin DJ, Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23, 1011-27.
  50. Howlader N, Noone AM, Krapcho M, et al (2011). SEER cancer statistics review, 1975-2008, national cancer institute. Bethesda, MD,, based on November 2010 SEER data submission, posted to the SEER web site.
  51. Ilyin SE, Belkowski SM, Plata-Salaman CR (2004). Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol, 22, 411-6.
  52. Isshiki S, Akakura K, Komiya A, et al (2002). Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol, 167, 512-5.
  53. Ito K (2014). Prostate cancer in Asian men. Nat Rev Urol, 11, 197-212.
  54. Jaggi M, Nazemi T, Abrahams NA, et al (2006). N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate, 66, 193-9.
  55. Jiang Z, Wu CL, Woda BA, et al (2004). Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathol, 45, 218-25.
  56. Jung K, Brux B, Lein M, et al (2000). Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem, 46, 47-54.
  57. Karnes RJ, Bergstralh EJ, Davicioni E, et al (2013). Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol, 190, 2047-53.
  58. Kattan MW, Shariat SF, Andrews B, et al (2003). The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol, 21, 3573-9.
  59. Khan MO, Ather MH (2011). Chromogranin a serum marker for prostate cancer. JPMA, 61, 108-11.
  60. Kim H-S, Ingermann AR, Tsubaki J, et al (2004). Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res, 64, 2229-37.
  61. Kitagawa Y, Ueno S, Izumi K, et al (2014). Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening. J Cancer Res Clin Oncol, 140, 53-9.
  62. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al (2014). A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. European Urol, 66, 550-60.
  63. Koksal IT, Dirice E, Yasar D, et al (2004). The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol, 22, 307-12.
  64. Kollermann J HB (2001). Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J ClinPathol, 116, 115-21.
  65. Kuczyk MA, Bokemeyer C, Hartmann J, et al (2001). Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol Reports, 8, 1401-7.
  66. Kuniyasu H, Troncoso P, Johnston D, et al (2000). Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res, 6, 2295-308.
  67. Laitinen S, Martikainen PM, Tolonen T, et al (2008). EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Intern J Cancer, 122, 595-602.
  68. Larkin SET, Holmes S, Cree IA, et al (2012). Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer, 106, 157-65.
  69. Lawrence TS (2011). Cancer: Principles and Practice of Oncology. in eds Philadelphia, Pa: Lippincott Williams & Wilkins, 2011, 1220-71.
  70. Li R, Heydon K, Hammond ME, et al (2004a). Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res, 10, 4118-24.
  71. Li R, Younes M, Wheeler TM, et al (2004b). Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate, 58, 193-9.
  72. Li Y, Su J, DingZhang X, et al (2011). PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol, 224, 90-100.
  73. Lin DW (2009). Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol, 27, 315-21.
  74. Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ (2012). Prostate-specific antigen velocity risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int, 109, 508-13
  75. Lopergolo A, Zaffaroni N (2009). Biomolecular markers of outcome prediction in prostate cancer. Cancer, 115, 3058-67.
  76. Lotan TL, Gurel B, Sutcliffe S, et al (2011). PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res, 17, 6563-73.
  77. Madu Co LY (2010). Novel diagnostic biomarkers for prostate cancer. J Cancer, 1, 150-77.
  78. Aghaei M, Panjehpour M, Karami-Tehrani F, Salami S (2011). Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol, 137, 1511-23.
  79. Marika J. Linja, Savinainen KJ, Saramaki OR, et al (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res, 61.
  80. Mehta HH, Gao Q, Galet C, et al (2011). IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res, 71, 5154-63.
  81. Michalaki V, Syrigos K, Charles P, et al (2004). Serum levels of IL-6 and TNF-${\alpha}$ correlate with clinicopathological features and patient survival in patients with prostate cancer. British J Cancer, 90, 2312-6.
  82. Mohammed AA (2014). Biomarkers in prostate cancer: new era and prospective. Med Oncol, 31, 140.
  83. Mulholland DJ, Tran LM, Li Y, et al (2011). Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell, 19, 792-804.
  84. Nakashima J, Tachibana M, Horiguchi Y, et al (2000). Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res, 6, 2702-6.
  85. Nixon RG, Wener MH, Smith KM, et al (1997). Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol, 157, 2183-90.
  86. Oxley JD, Winkler MH, Parry K, et al (2002). p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int, 89, 27-32.
  87. Panjehpour M, Movahedian A, Sadeghi H, et al (2012). Adenosine receptor expression in two different human cancer cell lines at molecular level. Iranian J Cancer Prev, 3, 111-6.
  88. Patel DA, Presti JC, McNeal JE, et al (2005). Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol, 23, 6157-62.
  89. Perry KT, Anthony CT, Case T, et al (1997). Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology, 49, 151-5.
  90. Pollack A, DeSilvio M, Khor LY, et al (2004). Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: radiation therapy oncology group trial 92-02. J Clin Oncol, 22, 2133-40.
  91. Quinn Di HsSMSRL (2005). Molecular markers of prostate cancer outcome. Eur J Cancer, 41, 858-87.
  92. Ramirez ML, Nelson EC, Evans CP (2008). Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer, 11, 216-29.
  93. Reiter RE, Gu Z, Watabe T, et al (1998). Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proceed Nat Acad Sci, 95, 1735-40.
  94. Reiter RE, Sato I, Thomas G, et al (2000). Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes, Chromosomes Cancer, 27, 95-103.<95::AID-GCC12>3.0.CO;2-3
  95. Riegman PHJ, Vlietstra RJ, Klaassen P, et al (1989). The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Letters, 247, 123-6.
  96. Rigaud J, Tiguert R, Decobert M, et al (2004). Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Prostate, 58, 269-76.
  97. Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al (1998). human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crc Cr Rev Cl Lab Sc, 35, 275-368.
  98. Rodriguez-Berriguete G, Sanchez-Espiridion B, Cansino JR, et al (2013). Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-${\alpha}$ signaling pathways in prostate cancer. Cytokine, 64, 555-63.
  99. Rosner IL, Ravindranath L, Furusato B, et al (2007). Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology, 70, 1225-9.
  100. Ross JS, Jennings TA, Nazeer T, et al (2003). Prognostic factors in prostate cancer. Am J Clin Pathol, 120, 85-100.
  101. Rubin MA, Mucci NR, Figurski J, et al (2001). E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology. Human Pathol, 32, 690-7.
  102. Rubio J, Ramos D, Lopez-Guerrero JA, et al (2005). Immunohistochemical expression of Ki-67 antigen, Cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. European Urol, 48, 745-51.
  103. Safarinejad MR, Shafiei N, Safarinejad S (2011). Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3. Growth Horm IGF Res, 21, 146-54.
  104. Sardana G, Dowell B, Diamandis EP (2008). Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem, 54, 1951-60.
  105. Schwarze SR, DePrimo SE, Grabert LM, et al (2002). Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem, 277, 14877-83.
  106. Shariat SF, Canto EI, Kattan MW, Slawin KM (2004). Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol, 6, 58-72.
  107. Shariat SF, Abdel-Aziz KF, Roehrborn CG, et al (2006). Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. European Urol, 49, 293-302.
  108. Shariat SF, Andrews B, Kattan MW, et al (2001). Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology, 58, 1008-15.
  109. Shariat SF, Karam JA, Margulis V, et al (2008a). New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Intern, 101, 675-83.
  110. Shariat SF, Kattan MW, Traxel E, et al (2004a). Association of Pre- and postoperative plasma levels of transforming growth factor ${\beta}1$ and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res, 10, 1992-9.
  111. Shariat SF, Lamb DJ, Kattan MW, et al (2002). Association of preoperative plasma levels of insulin-like growth factor i and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol, 20, 833-41.
  112. Shariat SF, Menesses-Diaz A, Kim IY, et al (2004b). Tissue expression of transforming growth factor-${\beta}1$ and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology, 63, 1191-7.
  113. Shariat SF, Walz J, Roehrborn CG, et al (2008b). Early postoperative plasma transforming growth factor-${\beta}1$ is a strong predictor of biochemical progression after radical prostatectomy. J Urol, 179, 1593-7.
  114. Siddiqui E, Mumtaz FH, Gelister J (2004). Understanding prostate cancer. J Royal Soc Promot Health, 124, 219-21.
  115. Society AC (2013). Can prostate cancer be found early? [Online]. Available:
  116. Southwick PC, Catalona WJ, Partin AW, et al (1999). Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol, 162, 1346-51.
  117. Sreekumar A, Laxman B, Rhodes DR, et al (2004). Humoral immune response to ${\alpha}$-Methylacyl-CoA racemase and prostate cancer. J Nat Cancer Inst, 96, 834-43.
  118. Stamey TA, Johnstone IM, McNeal JE, et al (2002). Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol, 167, 103-11.
  119. Thompson IM, Ankerst D, Chi C, et al (2005). OPerating characteristics of prostate-specific antigen in men with an initial psa level of 3.0 ng/ml or lower. JAMA, 294, 66-70.
  120. Timothy J Wilt, Ahmed HU (2013). Prostate cancer screening and the management of clinically localized disease. BMJ, 346, 325.
  121. Tricoli JV, Schoenfeldt M, Conley BA (2004). Detection of prostate cancer and predicting progression current and future diagnostic markers. Clin Cancer Res, 10, 3943-53.
  122. UK CR. (2012). Prostate cancer mortality statistics [Online]. Available:
  123. Van Veldhoven PP, Croes K, Casteels M, et al (1997). 2-methylacyl racemase: a coupled assay based on the use of pristanoyl-CoA oxidase/peroxidase and reinvestigation of its subcellular distribution in rat and human liver. Biochim Biophys Acta, 1347, 62-8.
  124. Vergis R, Corbishley CM, Norman AR, et al (2008). Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol, 9, 342-51.
  125. Wikstrom P, Damber J-E, Bergh A (2001). Role of transforming growth factor-${\beta}1$ in prostate cancer. Microsc Res Techniq, 52, 411-9.<411::AID-JEMT1026>3.0.CO;2-8
  126. Wolff JM, Fandel TH, Borchers H, et al (1999). Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases. Anticancer Res, 19, 2657-9.
  127. Yang J, Wu HF, Qian LX, et al (2006). Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression. Asian J Androl, 8, 169-75.
  128. Yoshimoto M, Cunha IW, Coudry RA, et al (2007). FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British J Cancer, 97, 678-85.
  129. Yu H, Nicar MR, Shi R, et al (2001). Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology, 57, 471-5.
  130. Yuan JJ, Coplen DE, Petros JA, et al (1992). Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol, 147, 810-4.
  131. Zhigang Z, Wenlv S (2004). Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Japanese J Clin Oncol, 34, 414-9.
  132. Zorn KC HP (2014). Prostate specific antigen [Online]. Available:

Cited by

  1. Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy vol.16, pp.12, 2015,
  2. Human Kallikrein-2, Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients vol.16, pp.16, 2015,
  3. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India vol.17, pp.4, 2016,
  4. Development of an Activatable Fluorescent Probe for Prostate Cancer Imaging vol.28, pp.8, 2017,
  5. Expression of fatty acid synthase and E-cadherin markers in cancer of the prostate vol.37, pp.1, 2017,
  6. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer vol.49, pp.5, 2017,
  7. Specific and reliable detection of Myosin 1C isoform A by RTqPCR in prostate cancer cells vol.6, pp.2167-8359, 2018,
  8. Chromogranin A as a biomarker for prostate cancer: is it actually relevant for clinical practice? vol.14, pp.13, 2018,
  9. PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer vol.18, pp.1, 2018,